Literature DB >> 28806222

Transient Receptor Potential Vanilloid 1 Antagonists Prevent Anesthesia-induced Hypothermia and Decrease Postincisional Opioid Dose Requirements in Rodents.

Andras Garami1, Mohab Ibrahim, Kerry Gilbraith, Rajesh Khanna, Eszter Pakai, Alexandra Miko, Erika Pinter, Andrej A Romanovsky, Frank Porreca, Amol M Patwardhan.   

Abstract

BACKGROUND: Intraoperative hypothermia and postoperative pain control are two important clinical challenges in anesthesiology. Transient receptor potential vanilloid 1 has been implicated both in thermoregulation and pain. Transient receptor potential vanilloid 1 antagonists were not advanced as analgesics in humans in part due to a side effect of hyperthermia. This study tested the hypothesis that a single, preincision injection of a transient receptor potential vanilloid 1 antagonist could prevent anesthesia-induced hypothermia and decrease the opioid requirement for postsurgical hypersensitivity.
METHODS: General anesthesia was induced in rats and mice with either isoflurane or ketamine, and animals were treated with transient receptor potential vanilloid 1 antagonists (AMG 517 or ABT-102). The core body temperature and oxygen consumption were monitored during anesthesia and the postanesthesia period. The effect of preincision AMG 517 on morphine-induced reversal of postincision hyperalgesia was evaluated in rats.
RESULTS: AMG 517 and ABT-102 dose-dependently prevented general anesthesia-induced hypothermia (mean ± SD; from 1.5° ± 0.1°C to 0.1° ± 0.1°C decrease; P < 0.001) without causing hyperthermia in the postanesthesia phase. Isoflurane-induced hypothermia was prevented by AMG 517 in wild-type but not in transient receptor potential vanilloid 1 knockout mice (n = 7 to 11 per group). The prevention of anesthesia-induced hypothermia by AMG 517 involved activation of brown fat thermogenesis with a possible contribution from changes in vasomotor tone. A single preincision dose of AMG 517 decreased the morphine dose requirement for the reduction of postincision thermal (12.6 ± 3.0 vs. 15.6 ± 1.0 s) and mechanical (6.8 ± 3.0 vs. 9.5 ± 3.0 g) withdrawal latencies.
CONCLUSIONS: These studies demonstrate that transient receptor potential vanilloid 1 antagonists prevent anesthesia-induced hypothermia and decrease opioid dose requirements for the reduction of postincisional hypersensitivity in rodents.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28806222     DOI: 10.1097/ALN.0000000000001812

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

1.  The opioid crisis and … reconsidering the use of drugs that affect body temperature.

Authors:  Amol Patwardhan; Frank Porreca; William K Schmidt; Andrej A Romanovsky
Journal:  Temperature (Austin)       Date:  2018-03-06

2.  Antinociceptive and genotoxic assessments of the antagonist TRPV1 receptor SB-366791 on morphine-induced tolerance in mice.

Authors:  Thiago Kastell Mazeto; Jaqueline Nascimento Picada; Áurea Pandolfo Correa; Isadora Nunes Rebelo; Magali Terra Ribeiro; Marcus Vinícius Gomez; Alessandra Hubner de Souza
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-10-26       Impact factor: 3.000

3.  Risks of Impaired Organ Protection with Inhibiting Transient Receptor Potential Vanilloid 1.

Authors:  Yu Wu; Eric R Gross; Jinqiao Qian
Journal:  Anesthesiology       Date:  2018-08       Impact factor: 8.986

Review 4.  Central Neural Circuits Orchestrating Thermogenesis, Sleep-Wakefulness States and General Anesthesia States.

Authors:  Jiayi Wu; Daiqiang Liu; Jiayan Li; Jia Sun; Yujie Huang; Shuang Zhang; Shaojie Gao; Wei Mei
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

5.  Body Temperature Measurements for Metabolic Phenotyping in Mice.

Authors:  Carola W Meyer; Youichirou Ootsuka; Andrej A Romanovsky
Journal:  Front Physiol       Date:  2017-07-31       Impact factor: 4.566

6.  TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds' pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development.

Authors:  A Garami; E Pakai; H A McDonald; R M Reilly; A Gomtsyan; J J Corrigan; E Pinter; D X D Zhu; S G Lehto; N R Gavva; P R Kym; A A Romanovsky
Journal:  Acta Physiol (Oxf)       Date:  2018-02-16       Impact factor: 6.311

Review 7.  Advances in TRP channel drug discovery: from target validation to clinical studies.

Authors:  Ari-Pekka Koivisto; Maria G Belvisi; Rachelle Gaudet; Arpad Szallasi
Journal:  Nat Rev Drug Discov       Date:  2021-09-15       Impact factor: 112.288

8.  Thermal Hyperalgesia and Mechanical Allodynia Elicited by Histamine and Non-histaminergic Itch Mediators: Respective Involvement of TRPV1 and TRPA1.

Authors:  Merab G Tsagareli; Ivliane Nozadze; Nana Tsiklauri; Mirela Iodi Carstens; Gulnaz Gurtskaia; E Carstens
Journal:  Neuroscience       Date:  2020-10-01       Impact factor: 3.590

9.  TRPV1 Inhibits the Ventilatory Response to Hypoxia in Adult Rats, but Not the CO₂-Drive to Breathe.

Authors:  Luis Gustavo A Patrone; Jaime B Duarte; Kênia Cardoso Bícego; Alexandre A Steiner; Andrej A Romanovsky; Luciane H Gargaglioni
Journal:  Pharmaceuticals (Basel)       Date:  2019-01-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.